A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o
A phase 3 trial of Zanidatamab, Trastuzumab, Eribulin in her2-positive breast cancer, run by Jazz Pharmaceuticals, now recruiting.
Overview
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer is a phase 3 interventional study registered as NCT06435429 by Jazz Pharmaceuticals, with 550 participants planned, started 2024-08-13 and due to reach its primary completion in 2028-04-28. Interventions recorded: Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine. Conditions listed: Metastatic HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine, Trastuzumab.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
- TrialA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Shares Eribulin, Capecitabine, Gemcitabine, HER2-positive breast cancer.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
- TrialA Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Shares Zanidatamab, Jazz Pharmaceuticals, Trastuzumab, HER2-positive breast cancer.
- TrialSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Shares Eribulin, Capecitabine, Gemcitabine.
- TrialA Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine.